Marimed Stock Investor Sentiment

MRMD Stock  USD 0.11  0.01  8.33%   
About 61% of Marimed's investor base is looking to short. The analysis of current outlook of investing in Marimed suggests that many traders are alarmed regarding Marimed's prospects. The current market sentiment, together with Marimed's historical and current headlines, can help investors time the market. In addition, many technical investors use Marimed stock news signals to limit their universe of possible portfolio assets.
Marimed otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Marimed daily returns and investor perception about the current price of Marimed as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at news.google.com         
The 7 Best Cannabis Stocks to Buy for April 2023 - InvestorPlace
Google News at Macroaxis
over a year ago at news.google.com         
MariMed Positioning Itself To Thrive In A Post-Rescheduling ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
WORLDS INC MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. - M...
Google News at Macroaxis
over a year ago at news.google.com         
Silver Spike Investment Corp. Reports Fiscal Year End 2022 ... - StreetInsider.com
Google News at Macroaxis
over a year ago at news.google.com         
Finding The Long Term Winners In The Cannabis Sector - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Cannabis MSO MariMed CEOs sudden death shows need for ... - Marijuana Business Daily
Google News at Macroaxis
over a year ago at news.google.com         
MariMed Announces Close on Acquisition of Ermont, Inc. Operating Assets - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
MariMed Inc. Q4 2022 Earnings Call Transcript - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
MARIMED INC. Managements Discussion and Analysis of Financial Condition and Results of Operations - ...
Google News at Macroaxis
over a year ago at news.google.com         
Transcript MariMed Inc., Q4 2022 Earnings Call, Mar 02, 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
MariMed Q4 Revenue Lifts 6 percent Sequentially New Cannabis Ventures - New Cannabis Ventures
Google News at Macroaxis
over a year ago at news.google.com         
Earnings Outlook For MariMed - MariMed - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
MariMed Stock Still Overlooked - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Cannabis Stock Movers For February 22, 2023 - HEXO , iAnthus Capital Hldgs , Mari - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
MariMed To Expand Footprint in Massachusetts With Dispensary Acquisition in Quincy - Marketscreener....
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Marimed that are available to investors today. That information is available publicly through Marimed media outlets and privately through word of mouth or via Marimed internal channels. However, regardless of the origin, that massive amount of Marimed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Marimed news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Marimed relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Marimed's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Marimed alpha.

Marimed Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15Dec2025Feb -25-20-15-10-50
JavaScript chart by amCharts 3.21.15Marimed Marimed Dividend Benchmark Dow Jones Industrial
       Timeline  

Complementary Tools for Marimed OTC Stock analysis

When running Marimed's price analysis, check to measure Marimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marimed is operating at the current time. Most of Marimed's value examination focuses on studying past and present price action to predict the probability of Marimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marimed's price. Additionally, you may evaluate how the addition of Marimed to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals